AMRI targets rare diseases
Pharmaceutical CDMO AMRI has invested both in terms of scale and compound handling capabilities and new expert personnel to address orphan and rare disease products. No figure has been disclosed of the sum involved.
At its headquarters site in Albany, New York, AMRI has added additional suites for 10-15 kg batch sizes. At Grafton, Wisconsin, it has expanded its hydrogenation, filtering and drying and analytical capabilities, the latter including LC-MS and GC-MS instruments, as well as new experts. The company has also expanded at Glasgow, UK.
Defined as those affecting fewer than 200,000 people in the US and fewer than one in 2,000 people in the EU, rare and orphan diseases accounted for the 31 of the 53 novel drug approvals by the FDA in 2020 and they have been projected to grow at 12%/year in prescription sales to 2026.